| Congresso Brasileiro de Microbiologia 2023 | Resumo: 61-1 | ||||
Resumo:The Candida auris species is a multi-drug resistant yeast capable of causing systemic and lethal infections. The virulence and increase in outbreaks worry the world, especially in hospitals where outbreaks are more recurrent. In many cases monotherapy is not effective, opting for drug combinations. However, resistance to antifungals increases over the years. In view of this, nanoemulsions (NEs) can be a nanotechnology strategy in the development of new therapeutic alternatives. Therefore, this study developed a co-encapsulated nanoemulsion with amphotericin B and micafungin (NEMA) in the control of infection caused by C. auris. NEs were developed in previous studies. Briefly, the NEs were composed of a mixture of 10% sunflower oil and cholesterol as the oil phase (5:1), 10% Polyoxyethylene (20) cetyl ether (Brij® 58) and soy phosphatidylcholine as surfactant/co-surfactant (2:1) and 80% PBS as the aqueous phase. The determination of the minimum inhibitory concentration (MIC90) and synergism assay (Checkerboard) was evaluated against the C. auris strain CDC B11903. Finally, the in vivo assay used Balb/c mice weighing between 25-28g and immunosuppressed (CEUA/FCF/CAr nº 29/2021). According to the results, MIC90 of the combination of micafungin + amphotericin B (MICAmB) and NEMA was 0.015 and 0.031 µg/mL, respectively. Furthermore, the combination of drugs showed a fractional inhibitory concentration index (FICI) <0.5 µg/mL, being synergistic against C. auris CDC B11903. Finally, the in vivo results show the surprising potentiate of the antifungal activity of the co-encapsulated drugs in NE, preventing yeast from causing infection in the lung and thymus. In conclusion, the combination of drugs to combat the infection caused by C. auris can be considered an efficient therapeutic option and nanoemulsions contribute to therapeutic potentiate, proving to be a promising new alternative. Palavras-chave: Candida auris, Infection desease , Nanoemulsion, Amphotericin B, Micafungin Agência de fomento:Fundação de amparo a pesquisa do estado de São Paulo - FAPESP nº 2019/09831-9 | |||||